Cardiodesfibrilador implantable. También se puede administrar un choque al corazón desde dentro del cuerpo con un cardiodesfibrilador implantable (CDI). Un desfibrilador cardioversor implantable (DCI) es un dispositivo que detecta cualquier latido cardíaco rápido y potencialmente mortal, llamado arritmia. Many translated example sentences containing “desfibrilador implantable” – English-Spanish dictionary and search engine for English translations.

Author: Zuluzilkree Zur
Country: Turkmenistan
Language: English (Spanish)
Genre: Finance
Published (Last): 13 January 2016
Pages: 92
PDF File Size: 2.43 Mb
ePub File Size: 13.38 Mb
ISBN: 133-3-12164-170-1
Downloads: 80014
Price: Free* [*Free Regsitration Required]
Uploader: Fenritaur

The transvenous implantable cardiac defibrillator T-ICD is currently considered the standard of care for prevention of sudden cardiac death in patients with structural cardiac disease or channelopathies. However, the use of these devices is associated with a significant increase of short and long-term complications, mostly related to intravascular leads.

The subcutaneous implantable cardiac defibrillator S-ICD is a novel alternative for high-risk patients susceptible to intravascular lead complications, with a similar efficacy as T-ICD. Multiple ongoing clinical trials involving the S-ICD cardiodesfibriladdor expected to provide additional information about safety, use and benefits in the clinical setting.

VHL Regional Portal

Sin embargo, el uso de estos dispositivos se asocia con un aumento significativo de complicaciones a corto y largo plazo, principalmente relacionadas con derivaciones intravasculares. Sudden cardiac death SCD represents one of the leading causes of death worldwide, particularly in patients who have channelopathies, arrhytmogenic hereditary disorders i. Brugada syndrome, long or short QT syndrome and structural cardiomyopathies including ischemic and non-ischemic cardiomyopathy.

The use of an implantable cardiac defibrillator ICD in conjunction with medical therapy have demonstrated a significant reduction of all-cause mortality, currently being the most effective strategy in reducing SCD, for both primary and secondary prevention.

First, the transvenous implantable cardiac defibrillator T-ICDwhich uses an intravascular lead for arrhythmia detection and cardiac stimulation; Second, the subcutaneous implantable cardiac defibrillator S-ICDwhich is composed of a pulse generator capable of detecting lethal ventricular arrhythmias and delivering high-energy depolarizing shocks through a subcutaneous parasternal lead.

Previous T-ICD required thoracotomy for their implantation. In contrast, modern devices use intravascular leads.

This has enabled cardiodeefibrilador to implant devices with a safer and less morbid technique, leading to a rapid increase in the number of devices implanted. Unfortunately, these devices have limited pacing capabilities, therefore, appropriate patient selection is crucial. In the following review article, we present an illustrative case-scenario, followed by an in-depth review of the topic.

Would this patient benefit from an S-ICD? Early complications associated with T-ICD implant occur in 3. The S-ICD consists of a pulse generator, located subcutaneously between the anterior and mid-axillary line at the fourth intercostal space. The pulse generator is connected to a single lead with two distal electrodes separated by an 8cm coil.

The electrodes are used for rhythm detection, while the coil delivers electrical shocks for the treatment of ventricular arrhythmias Figure 1. The cardiodesfibriladkr is tunneled through the subcutaneous tissue, running from the pulse generator to the xiphoid process and then running parallel to the left side of the sternum, fixed with non-absorbable sutures to reduce the risk of lead displacement, thus reducing the risk of ineffective or inappropriate shocks.

However, implantation requires enough subcutaneous tissue to provide appropriate protection of the device and reduce the risk of extrusion Figure 2which could be a limiting factor in thin individuals. Placement of the generator in an intermuscular pocket between the anterior surface of the Serratus anterior muscle and the posterior surface of the Latissimus dorsi muscle could potentially solve this problem, with a low risk of procedure-related complications hematomas, device erosion or infection.

The pulse generator is connected to a single lead, which has two electrodes proximal and distal and a single coil. This Figure belongs to Boston Scientific: Pocket location for insertion of the pulse generator.

Once pulse generator implantation is achieved, the lead is placed without the need of fluoroscopy. The two electrodes located at the cardiodesfibrilaxor of the xiphoid process and at the distal tip of the lead and the pulse generator create three electrocardiographic ECG vectors: The software automatically selects the ECG lead that provides the best QRS to Cardiodesfibriladof signal, reducing the risk of double counting and inappropriate shocks.


Location of the device and its lead once implanted. The position of the electrodes allows the construction of 3 electrical register vectors: Image taken and modified from http: After the device implantation, a defibrillation test DFT must be performed using a 65 J shock. Although routine DFT has been abandoned during T-ICD implants, the increased energy required for a successful defibrillation using subcutaneous devices due to a higher resistance to current flow, as opposed to a low resistance when the defibrillating coil is in direct contact with the myocardial surface along with a lack of trials comparing outcomes with and without DFT in impantable with an S-ICD make DFT mandatory.

Device and patient characteristics must be considered when deciding whether or not a patient is suitable for an S-ICD implant. Unlike the T-ICD, S-ICD cannot double as a pacemaker although it can provide 30 seconds of transthoracic pacing after a shock using mA biphasic pulse and should not be considered in patients who require cardiac pacing. This absence of implantabls capabilities includes a vardiodesfibrilador of anti-tachycardia pacing ATP.

However, simultaneous use of S-ICD with pacing devices leadless pacemakers, transvenous pacemakers or resynchronization devices have important limitations. Particularly, pacing from the apex produces significant distortion of the QRS-complex and T-wave morphology, limiting the number of patients suitable for S-ICD implant. As previously stated, thin patients have a risk of device extrusion due to insufficiently thick subcutaneous tissue, however, that is not an absolute contraindication although cardiodesfibripador should be taken into consideration upon implantation.

On the other hand, patients with a high risk of lead-related complications previous device infections, young males, athletes, patients on hemodialysis have a greater probability to benefit from an S-ICD. Most studies included patients with prior T-ICD infection, channelopathies such as Brugada syndrome, short and long QT syndrome or hypertrophic cardiomyopathy. The pooled analysis had a sample of patients, with a mean age of Once the patient is considered suitable for S-ICD implantation, a screening test must be performed.

This screening method evaluates sensing vectors in order to determine the ability to discriminate the QRS complex and the T-wave.

This is done using a specially designed tool, made of transparent plastic with different color profiles Figure 4. Subsequently, a rhythm strip is obtained by placing the ECG electrodes in a similar position to the device electrodes, enhancing the stimulation of the future sensing vectors Figure 5.

A description of the electrodes implantation is provided below:. To use it, a profile of the appropriate size is chosen according to the size of the QRS complex and the left border of the template is placed atthe beginning of the QRS complex, placing the baseline of the ECG trace at the baseline of the template. In the bottom part, two arrow-heads indicate cardiodefibrilador 14 cm that separate the proximal and distal electrodes.

Evaluation of the QRS complex and the T-wave using the template. A Once the appropriate template size is selected, the beginning of the QRS complex is aligned with the left border of the template red arrow and the ECG baseline with the line crossing through the profile.

Appropriate QRS and T-wave morpholgy are determined when the QRS complex exceeds superior or inferiorly the dashed line without exceeding the template limit and the T-wave does not exceed the final part of cardioesfibrilador template. B The QRS complex exceeds the template, and a larger template should be used for evaluation.

C The T-wave exceeds the template, which could lead to double counting and inappropriate shocks. D Low voltage QRS complex that does not exceed the dotted line. In this case, a implantablle template must be selected. One electrode located at the fifth intercostal space, in the left mid axillary line. This represents the future location of the device generator. One electrode located 1 cm to the left of the base of the xiphoid process.


This represents the future location of the proximal electrode. One electrode located in a left parasternal position, 14 cm above the previous electrode the tool includes a ruler to allow appropriate measurement. This represents the future location of the distal electrode. This is done by using an amplitude gain of mV. The baseline should be stable for adequate measurement and records should be taken in supine and standing positions.

Each of the QRS complexes, including premature ventricular complexes and Cardiodesfibrliador complexes stimulated by pacemakers, are evaluated to determine if the vector is appropriate for arrhythmia discrimination Figure 4. At least one of the leads must have adequate measurements in each of the anatomical positions recorded, otherwise the patient is not considered suitable for treatment with the S-ICD due to the risk of misinterpretation of the ECG.

Implantable cardioverter-defibrillator – Wikipedia

In previous studies, approximately A total of 59 episodes of ventricular rhythms VF and VT susceptible of being shocked were registered in both trials, with the S-ICD demonstrating a high rate of arrhythmia termination Implxntable rates vary widely, ranging from 1. Inappropriate shocks and rhythm identification algorithms: Device interrogation report of a patient with inappropriate shocks.

Low QRS-complex voltage in the selected sensing lead allowed for double and triple counting due to P-wave and T-wave oversensing. Manual cardiodesfbirilador using the primary cardiodesflbrilador as the sensing lead succesfully resolved P-wave and T-wave oversensing. Minor complications associated with device implantation: No direct comparisons have been performed between the transvenous and subcutaneous ICD, therefore, comparative superiority or non-inferiority of either device cannot be established.

The primary endpoint will be Implantablee adverse events and is scheduled to be completed by December Advantages and disadvantages of the S-ICD. When to consider an S-ICD as a recommended choice, as a reasonable choice or avoid it. Since the patient had multiple risk factors for lead-related complications young age, hemodialysis, high risk of SCDhe was considered a suitable candidate for S-ICD implantation.

Although the patient had previous non-sustained VT on Holter monitoring, the risks associated with an intravascular lead in young patients on hemodialysis outweighed the potential benefits of ATP. The procedure was undertaken uneventfully under local anesthesia, with a total procedure time of 35 minutes.

Patients most likely to benefit the most include young population, patients with a low risk of short-term shocks, patients with a past medical history of infections associated with cardiac stimulation devices, patients with conditions that limit vascular access for lead placement i.

Second generation devices have a longer longevity, smaller generator size and optimization of arrhythmia detection software. Current limitations include the significant rate of inappropriate shocks, inability to work as a pacemaker and the high costs. A randomized study of the prevention of sudden death in patients with coronary artery disease.

N Engl J Med. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. Rev Esp Cardiol Engl Ed.

Subcutaneous implantable cardioverter defibrillator. Termination of malignant ventricular arrhythmias with an implanted cardiodefsibrilador defibrillator in human beings. J Am Coll Cardiol. Improvements in 25 years of implantable cardioverter defibrillator therapy.

Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. A systematic cardiodesdibrilador of ICD complications in randomized controlled trials versus registries: Intermuscular pocket for subcutaneous implantable cardiodesfobrilador defibrillator: Intermuscular technique for implantation of the subcutaneous implantable cardioverter defibrillator: Intermuscular two-incision technique for subcutaneous impalntable cardioverter defibrillator implantation: Reduction careiodesfibrilador inappropriate therapy and mortality through ICD Programming.